Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (not Serina Therapeutics, Inc.) on August 12, 2022. The filing serves to announce the company's financial results for the three-month period ended June 30, 2022. AgeX is an emerging growth company incorporated in Delaware, with its principal executive offices in Alameda, California. Its common stock trades on the NYSE American under the symbol AGE.
Key Financial Metrics
The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It explicitly states that the detailed financial results are contained in a press release furnished as Exhibit 99.1. Consequently, no specific financial metrics can be extracted from the provided text.
Material Changes
The filing does not provide data to compare current period performance against prior comparable periods. The document acts solely as a notification that the Q2 2022 results have been released via a press release.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer regarding forward-looking statements. It notes that statements containing words such as "may," "will," "believes," or "expects" are forward-looking and subject to risks and uncertainties. The registrant disclaims any obligation to update these statements. Investors are directed to the "Risk Factors" section of AgeX's periodic SEC reports for additional details on factors that could cause actual results to differ materially from anticipated results.
Important Facts for Investor Verification
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated August 12, 2022), as they are not included in the body of this 8-K.
- Confirm the company name is AgeX Therapeutics, Inc., as the input metadata incorrectly referenced "Serina Therapeutics, Inc."
- Note that the information in Item 2.02 and the attached press release is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
- Review the company's most recent periodic reports for the full list of risk factors associated with its operations and forward-looking statements.